TP53 and ovarian cancer: Meijer et al. reported that a small chemical compound termed Nutlin-3, which binds to MDM2 and inhibits its interaction with p53, preferentially enhances drug-sensitivity of wild-type p53-expressing ovarian cancer cells through the accumulation of wild-type p53 [84].